Search results for ''

AASLD/EASL HBV Treatment Endpoints Workshop

September 08-09, 2016

Alexandria, VA, USA

AASLD and EASL possess the expertise in chronic hepatitis B and D to bridge the current knowledge gaps that regulatory and pharmaceutical industry has identified as important issues hampering development of novel therapeutic agents for chronic hepatitis B and D.

This workshop will bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

Read more »

Published on 29/08/2016

La Croix – Macron pousse la « French Tech » à se déployer dans les régions

http://www.la-croix.com/Economie/France/Macron-pousse-la-French-Tech-a-se-deployer-dans-les-regions-2016-07-25-1200778100

Published on 25/07/2016

CNRS Innovation – ENYO Pharma : un financement pour accélérer le développement d’un nouveau traitement de l’hépatite B

http://www.cnrs.fr/cnrsinnovation-lalettre/actus.php?numero=360

Published on 22/06/2016

ENS Lyon – ENYO Pharma : un financement pour accélérer le développement d’un nouveau traitement de l’hépatite B

http://www.ens-lyon.fr/valorisation/enyo-pharma-un-financement-pour-accelerer-le-developpement-d-un-nouveau-traitement-de-l-hepatite-b-314047.kjsp?RH=ENS-LYON-FR-RECH-VAL

Published on 20/06/2016

2016 BIO International Convention

June 6-9, 2016

Moscone Center, San Francisco, CA, USA

The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

http://convention.bio.org

Read more »

Published on 27/05/2016